Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04998669 · ClinicalTrials.gov registry record · Phase 2
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma, sponsored by Juan P. Alderuccio, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT04998669: Recruiting Phase 2 study of Follicular Lymphoma, sponsored by Juan P. Alderuccio, MD.
NCT04998669 is a Phase 2 study of Follicular Lymphoma that is actively recruiting participants, run by Juan P. Alderuccio, MD. The registered enrollment target is 100 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04998669, a Phase 2 study of Follicular Lymphoma, is actively recruiting participants, sponsored by Juan P. Alderuccio, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
Primary Outcome
Complete Response rate will be reported as the number of participants achieving complete response (CR) to study therapy. Response to therapy will be assessed using Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) (FDG-PET)/ Computerized Tomography (CT) following Lugano 2014 criteria by week 12 of treatment.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Loncastuximab tesirine
Study Locations (5)
Florida
- Florida Cancer Specialists and Research Institute - Fort Myers
- University of Miami - Miami
Michigan
- University of Michigan - Ann Arbor
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Pennsylvania
- Allegheny Health Network - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 2 |
What NCT04998669 shows while recruiting
NCT04998669 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT04998669 lists 5 locations in 4 states (Florida, Michigan, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04998669 about?
NCT04998669 is a clinical study titled "Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma". The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
What is the current status of trial NCT04998669?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2022-02-11. Estimated completion is 2030-08-01.
What conditions does trial NCT04998669 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT04998669?
The interventions under investigation include: Rituximab (DRUG), Loncastuximab tesirine (DRUG).
Who is sponsoring clinical trial NCT04998669?
This trial is sponsored by Juan P. Alderuccio, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04998669 being conducted?
This trial has 5 study locations across Florida, Michigan, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04998669's enrollment target sits among peer trials
100 30th of 89 higher than 57 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI